Thesis Summary
AbbVie Inc. (ABBV) seems, on the surface, like an incredibly undervalued stock offering a 4.75% dividend yield with a payout ratio of under 50%. Upon further inspection though, it becomes clear that due to is dependence on HUMIRA, its best days may be behind it. Still, considering the dividend and growth prospects, I rate AbbVie a strong buy with a price target of $135 according to my 10-year DCF valuation.
Source: Siemens Digital Industries Software
Company Overview
ABBV is a pharmaceutical company operating worldwide. The company develops and commercializes drugs, of